Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Sep 19, 2019
Bullish signal from Tickeron’s Trend Prediction Engine for Zoetis

Bullish signal from Tickeron’s Trend Prediction Engine for Zoetis

Zoetis (NYSE: ZTS) is a somewhat unique company in that it makes pharmaceuticals for animals. The New Jersey-based company makes drugs for all different animal species from dogs and cats to cows and horses. The company has performed extremely well in recent years, both fundamentally and in its price performance.

Zoetis just saw a bullish signal generated by the Tickeron Trend Prediction Engine on September 15. The signal calls for a gain of at least 4% within the next month and it% showed a confidence level of 74%. Past predictions for Zoetis have been successful 76% of the time.

Looking at the daily chart for the stock we see that the stock has been trending higher since December and a trend channel has formed to define the various cycles within the overall upward trend. The stock just bounced off the lower rail of the channel this week and it looks poised to move higher yet again.

 

Two other things that stand out on the chart are the 50-day moving average and the stochastic readings. The 5o-day is just above the lower rail of the channel and that gives the stock two potential support levels. The stochastic readings reached oversold territory last week and made a bullish crossover on September 17.

The bullish signal from Tickeron and the bullish stochastic crossover are both good signs for the stock, but there is even more evidence pointing to a move higher. The Tickeron Technical Analysis Overview shows that the lower Bollinger Band was broken on September 10. This price move signals that Zoetis may jump back above the lower band and head toward the middle band. In 29 of 42 cases where the stock price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued uptrend are 69%.

I mentioned earlier that the company has performed well from a fundamental perspective. At present the company boasts a return on equity of 77.1% and a profit margin of 32.1%. Both of those figures are excellent and well above average.

Zoetis has seen its earnings grow by an average of 25% per year over the last three years and they grew by 17% in the most recent quarterly report. Analysts expect earnings to grow by 14% in 2019 as a whole.

The Tickeron SMR rating for this company is 8, indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating for Zoetis is 2, indicating low risk on high returns. The average Profit vs. Risk Rating for the industry is 92, placing this stock better than average.

The Tickeron Price Growth Rating for Zoetis is 5, indicating outstanding price growth. Zoetis’ price has grown at a higher rate over the last 12 months as compared to S&P 500 index constituents. A rating of 1 points to highest price growth (largest percent return) while a rating of 100 points to lowest price growth (smallest percent return).

Sentiment toward Zoetis is average. There are 16 analysts covering the stock with 10 “buy” ratings, five “hold” ratings, and one “sell” rating. This puts the buy percentage at 62.5% and that is slightly below average, or slightly skewed toward the bearish side.

The short interest ratio is currently at 2.0 and that is also slightly below average, but that indicates a slight bullish skew.

Overall we see strong fundamentals, bullish signals from three different sources, and sentiment that is average. I would say thinks look pretty good for Zoetis in the coming weeks.

Related Ticker: ZTS

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


ZTS in upward trend: 10-day moving average moved above 50-day moving average on August 26, 2026

The 10-day moving average for ZTS crossed bullishly above the 50-day moving average on August 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ZTS just turned positive on August 19, 2026. Looking at past instances where ZTS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

ZTS moved above its 50-day moving average on August 28, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZTS advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

ZTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 206 cases where ZTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where ZTS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZTS as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.950) is normal, around the industry mean (47.010). P/E Ratio (12.367) is within average values for comparable stocks, (93.888). ZTS's Projected Growth (PEG Ratio) (7.055) is very high in comparison to the industry average of (1.974). Dividend Yield (0.028) settles around the average of (0.028) among similar stocks. P/S Ratio (3.427) is also within normal values, averaging (177.089).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ZTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.09B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 37%. GELS experienced the highest price growth at 62%, while BTAI experienced the biggest fall at -59%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -36% and the average quarterly volume growth was 73%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 64
Price Growth Rating: 55
SMR Rating: 87
Profit Risk Rating: 82
Seasonality Score: -15 (-100 ... +100)
View a ticker or compare two or three
ZTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a pet medication company

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Generic
Address
10 Sylvan Way
Phone
+1 973 822-7000
Employees
14500
Web
https://www.zoetis.com
Interact to see
Advertisement
Alamo Group reported Q4 2025 EPS of about 1.70 dollars, well below analyst expectations that were in the low‑2 dollar range, producing a sizable negative earnings surprise. Quarterly revenue came in around 373.7 million dollars, down roughly 3% year over year and about 7–8% below consensus estimates near 405 million dollars, signaling softer demand than the market anticipated.
Hycroft Mining Holding Corp (HYMC) shares slid more than 12% today as traders digested the company’s newly filed 2025 annual report, a major corporate update, and an extended development timeline that shifts the story further away from near‑term production and cash flow.
PicS (PICS) shares dropped more than 12% today as investors reacted to mounting concerns about valuation, elevated volatility, and uncertainty ahead of the company’s next earnings report later in March.
Shares of MOBX surged approximately +532.77% in the March 3, 2026 trading session, closing at $1.12 versus a prior close of $0.18. The primary catalyst was a major production purchase order from the U.S. Navy for components used in the Tomahawk cruise missile program.
DAKT shares are declining approximately -10% in Wednesday's session, trading near $23.91, compared to the prior close of approximately $26.57. The primary catalyst is the pre-market release of fiscal Q3 2026 earnings, in which diluted EPS of $0.06 fell significantly short of the consensus estimate of approximately $0.13–$0.15.
Shares of HRZN plunged approximately 23% in Wednesday's trading session — one of the steepest single-day declines in the company's recent history. Primary catalyst: Q4 2025 earnings released after the close on March 3 revealed net investment income (NII) per share of just $0.18, badly missing the consensus estimate of $0.26 and marking a steep sequential decline.
Palantir (PLTR) is outperforming a struggling market, rallying strongly over the past few sessions while approaching a critical resistance level near $143. With geopolitical tensions rising and defense analytics demand growing, the stock sits at a pivotal technical moment that could determine its next major move.
Investors holding record levels of protective puts means downside is heavily hedged, which often dampens crash risk but supports higher implied volatility (VIX) in the short run. The fact that the S&P 500 and Nasdaq are rising while hedging is surging suggests a “wall of worry” market: people are bullish enough to stay in, but nervous enough to pay up for insurance.
During the week of 9–15 February 2026, major U.S. equity indices finished lower overall, while Tickeron’s trending AI trading bots produced positive returns, particularly in defense and energy—two areas now directly affected by the newly opened war in Iran. With macro risk rising and volatility picking up, this divergence matters: it shows how sector‑focused, rules‑based AI strategies can still find upside when broad index exposure is negative.
Investors are furiously hedging against a potential credit market crash, just as geopolitical risk explodes with a new war in Iran. Put option open interest on major U.S. credit ETFs like HYG, JNK, LQD, and BKLN has surged to a record ~11.5 million contracts, doubling over the last 12 months and already exceeding the 2022 bear‑market peak of 10 million.
The current gap between single‑stock implied volatility and index volatility is back near October 2008 extremes, signaling that investors expect idiosyncratic risk (stock‑specific jumps) to dominate.
The HUBB/AVGO/ITA/QQQ robot is a multi-sector swing trader with a 5-minute entry / daily exit structure, capturing macro megatrends across defense, semiconductors, infrastructure, and growth tech. The LRCX/TER/AMAT/KLAC/AMKR/ASML robot is a concentrated intraday-to-swing trader operating exclusively in semiconductor equipment — one of the highest-volatility sectors in the market — on a 60-minute timeframe.
Tickeron's Defense PPA AI Trading Agent is an automated swing trading system focused exclusively on PPA — the Invesco Aerospace & Defense ETF. Designed with a 60-minute entry timeframe and daily timeframe exit signals, the robot balances intraday precision with longer-duration swing holding, allowing it to capture meaningful price moves in one of the most momentum-driven sectors of 2025–2026.
MRNA surged approximately +16.07% on March 4, 2026, closing at $57.84, up from the prior session's close of $49.83. The primary catalyst was Moderna's announcement of a landmark settlement in its long-running patent dispute over lipid nanoparticle (LNP) technology used in its mRNA vaccines.
Shares of The Trade Desk (TTD) surged +28.05% on March 5, 2026, reaching $32.23 from a prior close of $25.17. The primary catalyst was CEO Jeff Green's record insider purchase of approximately 6 million shares worth ~$148 million — the largest insider buy in the company's history.
AEO shares are trading at $19.89, down $2.56 or -11.40% from the prior session's close of $22.45. The primary catalyst is deeply disappointing Q1 fiscal 2026 operating income guidance of just $20–$25 million, which badly missed analyst expectations.
CIEN shares plunged 14.25% on March 5, 2026, trading at $294.59 versus the prior session's close of $343.55 — a decline of $48.96 per share. The steep sell-off came despite a strong earnings beat: adjusted EPS of $1.35 crushed the consensus estimate of $1.05 by 28.6%, and revenue of $1.43 billion rose 33% year-over-year.
Shares of Victoria's Secret & Co. (VSCO) tumbled approximately 11.87% in early trading on March 5, falling from a prior close of $60.01 to an intraday price near $52.89, with an intraday low of $51.61. The steep decline came despite a Q4 2025 earnings beat, with adjusted EPS of $2.77 topping the consensus estimate of $2.46 and revenue of $2.27 billion exceeding the expected $2.22 billion.
AMPX shares surged +18.57% in today's session, trading at $14.88 versus the prior close of $12.55. Primary catalyst: Q4 and full-year fiscal 2025 earnings, reported before the open, delivered a decisive beat on both EPS and revenue expectations.
EXPE shares are trading up approximately +9.70% intraday on March 5, 2026, rising from a prior close of $221.25 to around $242.71. March 5 is the stock's ex-dividend date for a newly raised quarterly dividend of $0.48 per share — a 20% increase from the prior payout — signaling strong management confidence in cash generation.